Organon & Co.

NYSE

Market Cap.

2.61B

Avg. Volume

5.89M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Organon & Co.

Organon & Co. News

Organon & Co. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareDrug Manufacturers - General
organon.com

About Organon & Co.

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Organon & Co. Earnings & Revenue

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

Organon & Co. Financials

Table Compare

Compare OGN metrics with:

   

Earnings & Growth

OGN

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

OGN

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

OGN

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

OGN

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Organon & Co. Income

Organon & Co. Balance Sheet

Organon & Co. Cash Flow

Organon & Co. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioStrong Sell
Price/Earnings RatioSell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Organon & Co. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

0.8600

Payment DateDividendFrequency
2025-06-120.02Quarterly
2025-03-130.28Quarterly
2024-12-120.28Quarterly
2024-09-120.28Quarterly
2024-06-130.28Quarterly

Historical Market Cap

Shares Outstanding

Organon & Co. Executives

NameRole
Mr. Kevin AliChief Executive Officer & Director
Mr. Matthew M. Walsh C.F.A.Executive Vice President & Chief Financial Officer
Mr. Joseph T. Morrissey Jr.Executive Vice President and Head of Manufacturing & Supply
Mr. Kirke WeaverExecutive Vice President, General Counsel & Corporate Secretary
Dr. Juan Camilo Arjona Ferreira M.D.Executive Vice President, Head of Research & Development and Chief Medical Officer
NameRoleGenderDate of BirthPay
Mr. Kevin AliChief Executive Officer & DirectorMale19605.21M
Mr. Matthew M. Walsh C.F.A.Executive Vice President & Chief Financial OfficerMale19672.07M
Mr. Joseph T. Morrissey Jr.Executive Vice President and Head of Manufacturing & SupplyMale19651.75M
Mr. Kirke WeaverExecutive Vice President, General Counsel & Corporate SecretaryMale19741.44M
Dr. Juan Camilo Arjona Ferreira M.D.Executive Vice President, Head of Research & Development and Chief Medical Officer19711.43M

Organon & Co. Insider Trades

Date15 May
NameHolzbaur Lynette
RoleSVP and Corporate Controller
TransactionDisposed
Type
Shares0
Date31 Mar
NameHolzbaur Lynette
RoleSVP and Corporate Controller
TransactionDisposed
Type
Shares20147
Date14 May
NameCOX CARRIE SMITH
RoleDirector
TransactionAcquired
TypeP-Purchase
Shares12469
Date7 May
NameFalcione Aaron
RoleChief Human Resources Officer
TransactionAcquired
TypeP-Purchase
Shares5500
Date6 May
NameWeaver Kirke
RoleGen. Counsel & Corp. Secy.
TransactionAcquired
TypeP-Purchase
Shares8045
DateNameRoleTransactionTypeShares
15 MayHolzbaur LynetteSVP and Corporate ControllerDisposed0
31 MarHolzbaur LynetteSVP and Corporate ControllerDisposed20147
14 MayCOX CARRIE SMITHDirectorAcquiredP-Purchase12469
7 MayFalcione AaronChief Human Resources OfficerAcquiredP-Purchase5500
6 MayWeaver KirkeGen. Counsel & Corp. Secy.AcquiredP-Purchase8045

Discover More

Streamlined Academy

Organon & Co.

NYSE

Market Cap.

2.61B

Avg. Volume

5.89M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Organon & Co. News

Organon & Co. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Organon & Co. Earnings & Revenue

Organon & Co. Income

Organon & Co. Balance Sheet

Organon & Co. Cash Flow

Organon & Co. Financials Over Time

Organon & Co. Executives

NameRole
Mr. Kevin AliChief Executive Officer & Director
Mr. Matthew M. Walsh C.F.A.Executive Vice President & Chief Financial Officer
Mr. Joseph T. Morrissey Jr.Executive Vice President and Head of Manufacturing & Supply
Mr. Kirke WeaverExecutive Vice President, General Counsel & Corporate Secretary
Dr. Juan Camilo Arjona Ferreira M.D.Executive Vice President, Head of Research & Development and Chief Medical Officer
NameRoleGenderDate of BirthPay
Mr. Kevin AliChief Executive Officer & DirectorMale19605.21M
Mr. Matthew M. Walsh C.F.A.Executive Vice President & Chief Financial OfficerMale19672.07M
Mr. Joseph T. Morrissey Jr.Executive Vice President and Head of Manufacturing & SupplyMale19651.75M
Mr. Kirke WeaverExecutive Vice President, General Counsel & Corporate SecretaryMale19741.44M
Dr. Juan Camilo Arjona Ferreira M.D.Executive Vice President, Head of Research & Development and Chief Medical Officer19711.43M

Organon & Co. Insider Trades

Date15 May
NameHolzbaur Lynette
RoleSVP and Corporate Controller
TransactionDisposed
Type
Shares0
Date31 Mar
NameHolzbaur Lynette
RoleSVP and Corporate Controller
TransactionDisposed
Type
Shares20147
Date14 May
NameCOX CARRIE SMITH
RoleDirector
TransactionAcquired
TypeP-Purchase
Shares12469
Date7 May
NameFalcione Aaron
RoleChief Human Resources Officer
TransactionAcquired
TypeP-Purchase
Shares5500
Date6 May
NameWeaver Kirke
RoleGen. Counsel & Corp. Secy.
TransactionAcquired
TypeP-Purchase
Shares8045
DateNameRoleTransactionTypeShares
15 MayHolzbaur LynetteSVP and Corporate ControllerDisposed0
31 MarHolzbaur LynetteSVP and Corporate ControllerDisposed20147
14 MayCOX CARRIE SMITHDirectorAcquiredP-Purchase12469
7 MayFalcione AaronChief Human Resources OfficerAcquiredP-Purchase5500
6 MayWeaver KirkeGen. Counsel & Corp. Secy.AcquiredP-Purchase8045

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
organon.com

About Organon & Co.

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Organon & Co.

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

Organon & Co. Financials

Table Compare

Compare OGN metrics with:

   

Earnings & Growth

OGN

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

OGN

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

OGN

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

OGN

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Organon & Co. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

0.8600

Payment DateDividendFrequency
2025-06-120.02Quarterly
2025-03-130.28Quarterly
2024-12-120.28Quarterly
2024-09-120.28Quarterly
2024-06-130.28Quarterly

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioStrong Sell
Price/Earnings RatioSell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

The Secret to Analyzing Winning Stocks (Step-by-Step Examples Inside)